CHS™ Coated Ablation Catheter

About Corline Biomedical

Corline Biomedical, founded in 2005 and based in Uppsala, Sweden, has developed the Corline Heparin Conjugate (CHC™), a unique macromolecular technology that mimics the natural blood-compatible lining of blood vessels. The company operates a dual business model, generating revenue by supplying its CHS™ coating to medical device partners while advancing its proprietary pipeline, Renaparin® and Cytoparin™, in high-value regenerative medicine fields like kidney transplantation and cell therapy. Listed on Nasdaq First North (CORLINE), Corline leverages a strong scientific foundation of over 100 publications to drive innovation and partnerships in areas of significant unmet clinical need.

Therapeutic Areas